Drug Profile
Research programme: bicyclic p38 MAP kinase inhibitors - GlaxoSmithKline
Alternative Names: Bicyclic p38 MAP kinase inhibitors research programme - GlaxoSmithKlineLatest Information Update: 17 Jan 2008
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 07 Sep 2004 Preclinical trials in Rheumatoid arthritis in United Kingdom (unspecified route)